Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.02M Buy
4,063
+366
+10% +$78.7K 0.29% 77
2026
Q1
$804K Sell
3,697
-84
-2% -$18.6K 0.26% 88
2025
Q4
$864K Sell
3,781
-188
-5% -$42.8K 0.29% 71
2025
Q3
$919K Sell
3,969
-77
-2% -$15.7K 0.33% 65
2025
Q2
$751K Buy
4,046
+187
+5% +$34.8K 0.3% 77
2025
Q1
$809K Sell
3,859
-542
-12% -$105K 0.43% 49
2024
Q4
$782K Buy
4,401
+1,013
+30% +$186K 0.39% 54
2024
Q3
$669K Buy
3,388
+441
+15% +$82.3K 0.55% 47
2024
Q2
$505K Sell
2,947
-192
-6% -$31.8K 0.33% 62
2024
Q1
$572K Sell
3,139
-628
-17% -$108K 0.64% 41
2023
Q4
$584K Buy
+3,767
New +$549K 0.74% 34

Other funds holding ABBV

Sunpointe's ABBV Position: Q2 2026 in Review

Sunpointe increased its AbbVie (ABBV) stake by 9.9% in Q2 2026, buying an estimated $78.7K and bringing the position to 4,063 shares worth $1.02M. The position accounts for 0.29% of the portfolio, ranked #77.

Sunpointe first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Sunpointe held 4,063 shares of AbbVie worth $1.02M as of Q2 2026.
  • Sunpointe bought 366 AbbVie shares in Q2 2026, an estimated $78.7K.
  • AbbVie made up 0.29% of Sunpointe's portfolio in Q2 2026, its #77 holding.
  • Sunpointe first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Sunpointe's 13F filing for Q2 2026, filed 24 Jul 2026.